Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update. The Company completed a transformational year as we began the transition from a clinical research focused… Continue reading Alpha Cognition Provides Business Update

The Senate Health, Education, Labor and Pensions Committee held a hearing to address the soaring costs of prescription drugs in the U.S., with CEOs from Johnson & Johnson, Merck, and Bristol Myers Squibb in attendance. The bipartisan concern over high drug prices is underscored by statistics revealing that approximately 9 million American adults didn’t adhere… Continue reading Senators grill Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing

CVS Health’s fourth-quarter earnings report revealed revenue and adjusted earnings that surpassed expectations, yet the company downgraded its full-year profit outlook due to heightened medical costs affecting the broader insurance industry. The adjusted earnings forecast for 2024 was lowered to at least $8.30 per share, down from a previous guidance of $8.50 per share, while… Continue reading CVS beats estimates, but cuts full-year profit outlook on higher medical costs

Eli Lilly’s fourth-quarter earnings and revenue surpassed expectations, driven by the successful launch of its new weight loss drug, Zepbound, and increased prices for its diabetes treatment, Mounjaro. Zepbound, approved by U.S. regulators in November, generated $175.8 million in sales, with analysts predicting it could reach over a billion dollars in sales in its first… Continue reading Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue

King Charles III, aged 75, has recently been diagnosed with cancer, as announced by Buckingham Palace in a statement on Monday. The diagnosis was made during a hospital procedure for benign prostate enlargement, where a separate issue was noted. While the specific form and stage of the cancer were not disclosed, subsequent diagnostic tests have… Continue reading King Charles diagnosed with cancer

Novo Nordisk’s parent company has announced a $16.5 billion deal to acquire drug manufacturer Catalent, a move aimed at enhancing the supply chain for the weight loss injection Wegovy and diabetes shot Ozempic. Catalent, a key supplier for Novo Nordisk’s fill-finish work involved in filling and packaging syringes and injection pens for Wegovy, will see… Continue reading Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

Bristol Myers Squibb, one of the world’s leading pharmaceutical companies, reported strong quarterly earnings and revenue, surpassing Wall Street expectations. In the fourth quarter, the company achieved earnings per share of $1.70 (adjusted), exceeding the anticipated $1.53, while revenue reached $11.48 billion, surpassing the expected $11.19 billion. The revenue growth, up 1% from the previous… Continue reading Bristol Myers Squibb results top estimates as new drugs post strong sales growth 

Merck reported fourth-quarter revenue and adjusted earnings that exceeded estimates, propelled by strong demand for its cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a net quarterly loss, primarily due to charges related to a deal with Daiichi Sankyo to co-develop cancer treatments. Adjusted earnings per share were 3 cents, beating expectations… Continue reading Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales

Neurotech startup Synchron is intensifying production of its brain-computer interface (BCI), the Synchron Switch, as it progresses toward commercial release. The company recently acquired a minority stake in German manufacturer Acquandas, granting exclusive access to the manufacturer’s layering technology for medical devices. Synchron’s BCI is a stent-like device inserted through blood vessels, enabling individuals with… Continue reading Neuralink competitor Synchron to ramp up brain implant production with equity stake in manufacturer

Norway’s sovereign wealth fund, the largest globally, suggests that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly could become the first healthcare companies to join the trillion-dollar club. This speculation is fueled by the surging demand for diabetes and weight loss drugs, with Novo Nordisk recently reporting robust 2023 earnings, driven by the success… Continue reading Norway’s giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club

GlaxoSmithKline (GSK) has raised its long-term sales outlook following the successful launch of its respiratory syncytial virus (RSV) vaccine, Arexvy. The vaccine generated approximately £1.2 billion ($1.5 billion) in sales within six months of its market debut, exceeding the initial forecast of £900 million to £1 billion ($1.1 billion to $1.26 billion) for 2023. GSK… Continue reading GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost

Pfizer surprised analysts by posting an adjusted fourth-quarter profit, despite a decline in its COVID business performing better than expected. The company reversed approximately $3.5 billion in revenue related to the anticipated return of 6.5 million doses of its COVID drug, Paxlovid, from the U.S. government. This hit was less than the initially expected $4.2… Continue reading Pfizer beats earnings estimates as declining Covid business loses less revenue than expected